# Debate Matchup Judgment Report

- template_id: `judge_judge_blend_20260804a__debate_placement_active_20260320f`
- side_swap_group_id: `prop_0582__claude-fable-5-high__qwen3.8-max__tpl_placement_active_20260320f`
- topic_id: `prop_0582`
- matchup: **Claude Fable 5 (high)** vs **Qwen 3.8 Max**
- overall judged result (normalized): **Claude Fable 5 (high)**
- overall judged result (raw): **Claude Fable 5 (high)**
- mean entertainment: `7.50 / 10`
- mean signed normalized margin for `Claude Fable 5 (high)`: `+1.06`
- judgment rows: `6`
- swap_complete: `1`
- rating_eligible: `1`

**Motion:** Over the next five years, allowing Medicare to cover GLP-1–class anti-obesity drugs broadly will reduce total US healthcare spending after accounting for drug costs.

## Source Links

- [Debate A transcript](../../../transcripts/prop_0582__claude-fable-5-high__qwen3.8-max__s0__tpl_placement_active_20260320f.md): PRO = **Claude Fable 5 (high)**, CON = **Qwen 3.8 Max**
- [Debate B transcript](../../../transcripts/prop_0582__qwen3.8-max__claude-fable-5-high__s1__tpl_placement_active_20260320f.md): PRO = **Qwen 3.8 Max**, CON = **Claude Fable 5 (high)**
- [Rolling judgment CSV](../../../judgments/judge_results__judge_blend_20260804a.csv)
  Search for `side_swap_group_id=prop_0582__claude-fable-5-high__qwen3.8-max__tpl_placement_active_20260320f` or topic `prop_0582`.

## Debate A

- debate_id: `prop_0582__claude-fable-5-high__qwen3.8-max__s0__tpl_placement_active_20260320f`
- transcript: [read transcript](../../../transcripts/prop_0582__claude-fable-5-high__qwen3.8-max__s0__tpl_placement_active_20260320f.md)
- roles: PRO = **Claude Fable 5 (high)**, CON = **Qwen 3.8 Max**
- judged result: Split `2-1` for **Qwen 3.8 Max**.
- entertainment scores: `7`, `7`, `8`
- mean signed raw margin (PRO+): `-0.60`

| Judge | Winner | Signed Margin (PRO+) | Normalized | Entertainment |
| --- | --- | ---: | ---: | ---: |
| Grok 4.5 (high) | Qwen 3.8 Max | -1.2 | -1.36 | 7.0 |
| Kimi K2.6 | Claude Fable 5 (high) | +1.4 | +1.59 | 7.0 |
| Muse Spark 1.1 (high) | Qwen 3.8 Max | -2.0 | -2.12 | 8.0 |

### Judge Notes

- **Grok 4.5 (high)**: CON held the burden cleaner: broad coverage creates certain near-term drug spend whose break-even requires high expected avoided care per treated month across the full pool, not just trial-like tails. PRO's discontinuation contradiction and sick-skew points landed, and using C...
  Most decisive rebuttal noted: B's R2 expected-value math (2% MI example yielding ~$100 vs $400 break-even) directly undercut PRO's tail-event substitution.
- **Kimi K2.6**: PRO built the stronger path to victory by exposing an internal tension in CON's case between continuous-treatment cost projections and high discontinuation, then converting that into a cost-capping argument. PRO successfully pressed CON to commit to specific numbers in Rebutta...
  Most decisive rebuttal noted: PRO's first rebuttal exposing CON's tension between "millions continuously treated" and "rampant discontinuation," which PRO leveraged into a decisive cost-capping mechanism; and PRO's closing synthesis using CON's own $20 billion commitment to show the math breaks in PRO's fa...
- **Muse Spark 1.1 (high)**: CON won the expected-value ledger clash. PRO framed savings around dramatic tail events (one prevented MI ~$25k, one delayed dialysis $90k/year paying for 5-18 treatment-years) but CON showed broad coverage must clear ~$400 per treated month on average, not in tail cases. With...
  Most decisive rebuttal noted: CON's Rebuttal 2 expected-value math: 4M treatment-years ≈$20B over 5 years at $400/mo, requiring $400/month avoided care, vs $100/year from 2% MI risk – exposing PRO's tail-case averaging fallacy as decisive.

## Debate B

- debate_id: `prop_0582__qwen3.8-max__claude-fable-5-high__s1__tpl_placement_active_20260320f`
- transcript: [read transcript](../../../transcripts/prop_0582__qwen3.8-max__claude-fable-5-high__s1__tpl_placement_active_20260320f.md)
- roles: PRO = **Qwen 3.8 Max**, CON = **Claude Fable 5 (high)**
- judged result: Unanimous `3-0` for **Claude Fable 5 (high)**.
- entertainment scores: `8`, `8`, `7`
- mean signed raw margin (PRO+): `-2.50`

| Judge | Winner | Signed Margin (PRO+) | Normalized | Entertainment |
| --- | --- | ---: | ---: | ---: |
| Grok 4.5 (high) | Claude Fable 5 (high) | -2.3 | -2.61 | 8.0 |
| Kimi K2.6 | Claude Fable 5 (high) | -2.2 | -2.49 | 8.0 |
| Muse Spark 1.1 (high) | Claude Fable 5 (high) | -3.0 | -3.19 | 7.0 |

### Judge Notes

- **Grok 4.5 (high)**: CON won by locking the dilemma on "broadly" (either already-arriving narrow coverage or diluted low-risk pool) and converting PRO's own cascade offset numbers into a clean 3-5x shortfall versus trial NNT arithmetic inside five years. PRO's high-risk reframing and cascade empha...
  Most decisive rebuttal noted: B4.2 turning A4.2's 30-50 patient-years vs $150k against the 150-200 NNT from trials
- **Kimi K2.6**: CON checkmated PRO by combining PRO's own cost-per-cascade estimate with trial-derived effect sizes to show drug spending exceeds savings three- to five-fold even in the highest-risk population. PRO never recovered from this arithmetic trap or escaped CON's dilemma that "broad...
  Most decisive rebuttal noted: CON's Rebuttal 2 (B4.2), which accepted PRO's $150,000 cascade figure and demonstrated that dividing it by the 150–200 patient-years of therapy needed per event prevented still yields drug costs several times larger than savings—a decisive use of PRO's own ledger that PRO neve...
- **Muse Spark 1.1 (high)**: CON wins on arithmetic. PRO conceded one $150k cascade offsets only 30-50 patient-years [B4.2] while high-risk trials need ~150-200 patient-years per event prevented [A2/A4]. CON divided PRO's own figures to show 3-5x cost vs savings even in best case, and closed dilemma: broa...
  Most decisive rebuttal noted: A4.1-A4.2 turned PRO's 30-50 patient-years concession against 150-200 patient-years NNT to prove net spending increase even at $150k cascade, collapsing PRO's case.
